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Background: The risk of stroke after transfemoral aortic valve implantation (TAVI) due to dislodgement and subsequent embolization of debris 
from aortic arch atheroma or from the calcified valve itself ranges between 2 and 10%. The rate of clinically silent cerebral ischemia is yet unknown, 
but may be even higher.
Methods: Thirty-two patients who underwent TAVI using a balloon-expandable (n=22) or self-expandable (n=10) stent valve prosthesis were 
included into this descriptive study and compared to a historical control group of 21 patients undergoing open surgical aortic valve replacement. 
Periprocedural apparent and silent cerebral ischemia was assessed by neurological testing and serial cerebral diffusion-weighted (DW) magnetic 
resonance imaging (MRI) at baseline, at 3.4 (2.5-4.4) days after the procedure and at 3 months.
Results: TAVI was successful in all patients. After the procedure, new foci of restricted diffusion on cerebral DW MRI were found in 27/32 (84%) 
TAVI patients and were more frequent than after open surgery (10/21 patients [48%], p=0.011). These lesions were usually multiple (1-19 per 
patient) and dispersed in both hemispheres in a pattern suggesting cerebral embolization. Volumes of these lesions were significantly smaller after 
TAVI than after surgery (77 [59-94] vs. 224 [111-338] mm3, p<0.001). There were neither measurable impairments of neurocognitive function 
nor apparent neurological events during the in-hospital period among TAVI patients, but there was 1 (5%) stroke in the surgical patient group. On 
3-month follow-up DW-MRI, there were no new foci of restricted diffusion and there was no residual signal change associated with the majority 
(80%) of the foci detected in the periprocedural period.
Conclusions: Clinically silent new foci of restricted diffusion on cerebral MRI were detected in 84% of patients undergoing TAVI. Although typically 
multiple, these foci were not associated with apparent neurological events or measurable deterioration of neurocognitive function during 3-month 
follow-up. Further work needs to be directed to determine the clinical significance of these findings in a larger patient population.
